Sign Up Today and Learn More About Mediar Therapeutics Stock
Invest in or calculate the value of your shares in Mediar Therapeutics or other pre-IPO companies through EquityZen's platform.
Mediar Therapeutics Stock (MEDT)
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
About Mediar Therapeutics Stock
Founded
2019
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Mediar Therapeutics Press Mentions
Stay in the know about the latest news on Mediar Therapeutics
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
biospace • Feb 03, 2026
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
pharmiweb • Feb 03, 2026
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
businesswire • Feb 03, 2026
Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio
prnewswire • Feb 02, 2026
Mediar’s new $76m funding advances anti-fibrosis treatments
longevity • Jan 17, 2026
Mediar Therapeutics Management
Leadership team at Mediar Therapeutics
Executive chairman
Simon Sturge
CSO & Founder
Paul Yaworsky
Join now and verify your accreditation status to gain access to:
- Mediar Therapeutics Current Valuation
- Mediar Therapeutics Stock Price
- Mediar Therapeutics Management
- Available deals in Mediar Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Mediar Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Mediar Therapeutics Revenue and Financials
- Mediar Therapeutics Highlights
- Mediar Therapeutics Business Model
- Mediar Therapeutics Risk Factors
- Mediar Therapeutics Research Report from SACRA Research
Trading Mediar Therapeutics Stock
How to invest in Mediar Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Mediar Therapeutics through EquityZen funds. These investments are made available by existing Mediar Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Mediar Therapeutics stock?
Shareholders can sell their Mediar Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
